News
Displaying 111–120 of 536
-
Therapeutic Targets for Dry AMD: A Foundation Fighting Blindness Webinar for Eye Care Professionals
Foundation NewsThe free, online event will feature a lecture from David Boyer, MD, a Senior Partner at Retina-Vitreous Associates Medical Group and dry AMD expert.
-
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
Research NewsFirst cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
-
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
Research NewsThe AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
FDA Approves 8 MG Dosing of Eylea for Wet AMD, Diabetic Macular Edema, and Diabetic Retinopathy
Research NewsNew, higher treatment dose reduces frequency of eye injections for patients
-
IZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to Advanced Dry AMD
Research NewsIn two Phase 3 clinical trials, IZERVAY slowed the growth rate of lesions, the regions of cell loss in the central retina, associated with geographic atrophy (GA)
-
Karen Petrou Appointed Foundation Chair Effective July 1, 2024, Upon the Retirement of David Brint
Foundation NewsSpecial Foundation Announcement from Jason Menzo
-
Belite Bio Doses First Patient in Phase 3 Clinical Trial for Advanced Dry AMD (GA) Therapy
Research NewsThe company’s emerging, oral treatment is designed to slow vision loss
-
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
Research NewsThe emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
Research News
The five-year grant will advance the emerging treatments toward clinical trials
-
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
Research NewsAn emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
.png)
